Press Release: Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Bernstein Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $44
Tandem Diabetes Care (NASDAQ:TNDM) Shareholders Have Endured a 71% Loss From Investing in the Stock Three Years Ago
RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $65
Diabetes Device Maker Beta Bionics Files for $100M IPO
Tandem Diabetes Care Has Signed A Multi-Year Collaboration Agreement With The University Of Virginia Center For Diabetes Technology To Advance Research And Development Efforts On Fully Automated Closed-Loop Insulin Delivery Systems
Express News | Tandem Diabetes Care Enters Multi-Year Research Collaboration With Uva Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems
Bernstein Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $42
Express News | Benzinga Market Summary: S&P Rises On PCE Data, Novo Nordisk Falls On Weight Loss Data, Diabetes Stocks Rise
Express News | Tandem Diabetes Care Shares Are Trading Higher Amid Strength in Diabetes-related Stocks Following Weight Loss Data From Novo Nordisk
DexCom, Insulet, Tandem Benefit From Novo Nordisk CagriSema Data
RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)
The Market Lifts Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares 25% But It Can Do More
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $50
Express News | Tandem T:Slim X2 Insulin Pump Now Compatible With Dexcom G7 Cgm in Canada
Tandem T:slim X2 Insulin Pump Now Compatible With Dexcom G7 CGM in Canada
Express News | Tandem Diabetes Care Inc : Canaccord Genuity Raises Target Price to $63 From $56
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $40
Tandem Diabetes Care Poised for Growth: Expansion Into Type 2 Diabetes and Strategic Integration Drive Buy Rating